Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Mesoblast ( (MESO) ).
On January 6, 2026, Mesoblast Limited reported to the Australian Securities Exchange that 3,000,000 unquoted “Warrants 3” (ASX code MSBAB) had lapsed after the conditions attached to these securities were not, or could no longer be, satisfied, resulting in their cessation without any consideration paid. Following this lapse, Mesoblast confirmed that its issued capital comprised approximately 1.28 billion ordinary fully paid shares and a range of remaining unquoted options and warrants, signalling a modest simplification of its capital structure but no immediate change to its ordinary share count or cash position for existing shareholders.
The most recent analyst rating on (MESO) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong growth potential but significant financial challenges. The earnings call provided positive insights into market access and product launches, which are promising for future growth. However, financial performance and valuation concerns weigh down the score, with technical indicators suggesting caution due to overbought conditions.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australia-incorporated biotechnology company listed on the Australian Securities Exchange under the code MSB, focused on developing and commercializing cell-based therapies. The company’s capital structure includes a large base of ordinary fully paid shares as well as multiple classes of unquoted options and warrants, reflecting its reliance on equity-linked instruments to fund growth and incentivize stakeholders in the life sciences sector.
Average Trading Volume: 209,509
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.39B
See more data about MESO stock on TipRanks’ Stock Analysis page.